Bhavna Murali
Research Subjects
Bhavna Murali has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Adrian V. Lee
University of Pittsburgh
15 shared publications - Alexander Zheleznyak
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
15 shared publications - Carl J. DeSelm
Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO, USA
15 shared publications - David G. DeNardo
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
15 shared publications - Douglas V. Faget
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri
15 shared publications - Ganesh Kumar Raut
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA
15 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S10 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Contains supplemental figures and legends
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S10 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Contains supplemental figures and legends
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Table containing all of our reagents
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Table containing all of our reagents
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy
Table containing all of our reagents
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy
Table containing all of our reagents
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy
Table containing all of our reagents
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy
Table containing all of our reagents
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S10 from p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy
Contains supplemental figures and legends
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S10 from p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy
Contains supplemental figures and legends
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S10 from p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy
Contains supplemental figures and legends
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S10 from p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy
Contains supplemental figures and legends
- Open Access
- 2 May 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (19) , 1319-1331
Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact ® survey 2021
Aim: To report the treatment patterns of advanced/metastatic non-small-cell lung cancer (NSCLC) in China from a physician survey (CancerMPact®). Materials & methods: A total of 206 Chinese physicia... Plain language summary The most common type of lung cancer is called non-small-cell lung cancer (NSCLC). When lung cancer spreads beyond the lung, it is called advanced. Doctors in China who treat ...
- 2 May 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (19) , 1319-1331
Open AccessTreatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact ® survey 2021
Aim: To report the treatment patterns of advanced/metastatic non-small-cell lung cancer (NSCLC) in China from a physician survey (CancerMPact®). Materials & methods: A total of 206 Chinese physicia... Plain language summary The most common type of lung cancer is called non-small-cell lung cancer (NSCLC). When lung cancer spreads beyond the lung, it is called advanced. Doctors in China who treat ...
- Open Access
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Table containing all of our reagents
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Table containing all of our reagents
- Open Access
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S10 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Contains supplemental figures and legends
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S10 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Contains supplemental figures and legends
- Open Access
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Table containing all of our reagents
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Table containing all of our reagents